source
- Vor Bio pays RemeGen $10 million for rights to long-acting autoimmune drug candidate RC298Vor Bio announced a licensing agreement with RemeGen, paying $10 million upfront in cash and issuing warrants valued at about $46 million for rights to RC298 outside Greater China. RC298 is a long…
- Kyverna pauses development of next-gen autoimmune CAR-T KYV-102 to focus on neurologic miv-cel programKyverna Therapeutics announced it is halting work on its next-generation CD19 CAR-T candidate KYV-102, which had been positioned as a follow-up to its lead autoimmune CAR-T miv-cel. KYV-102 was de…